Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243189 · ClinicalTrials.gov registry record · Phase 1
Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
A Phase 1 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02243189 is a Phase 1 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 17 participants.
The verdict
NCT02243189, a Phase 1 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the cytokine levels in nasal lavage and gene expression in nasal scraping following a single nasal dose of JNJ-43260295 in healthy participants, and in atopic mild to mild-persistent asthmatic (breathing disorder in which there is wheezing and difficulty in breathing) participants with and without nasal allergen challenge prior to dosing.
Interventions
- DRUG Placebo
- DRUG JNJ-43260295
- DRUG Nasal Allergen Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02243189
The ClinicalTrials.gov registry entry for NCT02243189 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02243189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02243189 about?
NCT02243189 is a clinical study titled "Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma". The purpose of this study is to investigate the cytokine levels in nasal lavage and gene expression in nasal scraping following a single nasal dose of JNJ-43260295 in healthy participants, and in atopic mild to mild-persistent asthmatic (breathing disorder in which there is wheezing and difficulty i...
What is the current status of trial NCT02243189?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02243189?
The interventions under investigation include: Placebo (DRUG), JNJ-43260295 (DRUG), Nasal Allergen Challenge (DRUG).
Who is sponsoring clinical trial NCT02243189?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.